127 related articles for article (PubMed ID: 29084188)
1. [Evaluation of effect of indacaterol (Onbrez) and/or glycopyrronium (Seebri) treatment on Quality of Life of COPD patients in medical practice in Poland - observational study (OSQO)].
Płusa T; Physicians From Medical Centers In Poland GO
Pol Merkur Lekarski; 2017 Oct; 43(256):158-162. PubMed ID: 29084188
[TBL] [Abstract][Full Text] [Related]
2. GOLD 2017 treatment pathways in 'real life': An analysis of the DACCORD observational study.
Worth H; Buhl R; Criée CP; Kardos P; Lossi NS; Vogelmeier CF
Respir Med; 2017 Oct; 131():77-84. PubMed ID: 28947047
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of the LABA/LAMA dual bronchodilator indacaterol/glycopyrronium in a Swedish healthcare setting.
Price D; Keininger D; Costa-Scharplatz M; Mezzi K; Dimova M; Asukai Y; Ställberg B
Respir Med; 2014 Dec; 108(12):1786-93. PubMed ID: 25307414
[TBL] [Abstract][Full Text] [Related]
4. Pooled safety analysis of the fixed-dose combination of indacaterol and glycopyrronium (QVA149), its monocomponents, and tiotropium versus placebo in COPD patients.
Wedzicha JA; Dahl R; Buhl R; Schubert-Tennigkeit A; Chen H; D'Andrea P; Fogel R; Banerji D
Respir Med; 2014 Oct; 108(10):1498-507. PubMed ID: 25135743
[TBL] [Abstract][Full Text] [Related]
5. Improvement in health status with once-daily indacaterol/glycopyrronium 110/50 μg in COPD patients: real-world evidence from an observational study in Ireland.
O'Doherty B; Dorman J; McGrath K; Kelly K; Molony D; Lacey S; Whelan S; Schmid S; Sullivan S
Ir J Med Sci; 2019 Nov; 188(4):1251-1259. PubMed ID: 30924006
[TBL] [Abstract][Full Text] [Related]
6. Comparative effectiveness of indacaterol/glycopyrronium in the treatment of chronic obstructive pulmonary disease.
Cazzola M; Rogliani P
J Comp Eff Res; 2017 Oct; 6(7):627-636. PubMed ID: 28840753
[TBL] [Abstract][Full Text] [Related]
7. FLIGHT1 and FLIGHT2: Efficacy and Safety of QVA149 (Indacaterol/Glycopyrrolate) versus Its Monocomponents and Placebo in Patients with Chronic Obstructive Pulmonary Disease.
Mahler DA; Kerwin E; Ayers T; FowlerTaylor A; Maitra S; Thach C; Lloyd M; Patalano F; Banerji D
Am J Respir Crit Care Med; 2015 Nov; 192(9):1068-79. PubMed ID: 26177074
[TBL] [Abstract][Full Text] [Related]
8. Translational Study Searching for Synergy between Glycopyrronium and Indacaterol.
Cazzola M; Calzetta L; Segreti A; Facciolo F; Rogliani P; Matera MG
COPD; 2015 Apr; 12(2):175-81. PubMed ID: 25222881
[TBL] [Abstract][Full Text] [Related]
9. Coexisting Heart Failure and Chronic Obstructive Pulmonary Disease: Report of Two Cases Treated with Indacaterol/Glycopyrronium.
Cosentino ER; Degli Esposti D; Miceli R; Bentivenga C; Landolfo M; Ricci Iamino I; Spinardi L; Magri G; Borghi C
Respiration; 2018; 95 Suppl 1():3-5. PubMed ID: 29705784
[TBL] [Abstract][Full Text] [Related]
10. QVA149 (indacaterol/glycopyrronium) for the treatment of chronic obstructive pulmonary disease.
Matera MG; Rogliani P; Cazzola M
Expert Opin Pharmacother; 2015 May; 16(7):1079-90. PubMed ID: 25843089
[TBL] [Abstract][Full Text] [Related]
11. Treatment of chronic obstructive pulmonary disease by dual bronchodilation with coformulation of indacaterol/glycopyrronium.
Pelaia G; Maselli R; Matera MG
Pharmacology; 2014; 94(5-6):249-58. PubMed ID: 25471458
[TBL] [Abstract][Full Text] [Related]
12. Population pharmacokinetics of IND/GLY (indacaterol/glycopyrronium) in COPD patients.
Demin I; Bartels C; Graham G; Bieth B; Gautier A; Tillmann HC; Sechaud R
Int J Clin Pharmacol Ther; 2016 Jun; 54(6):405-15. PubMed ID: 27049057
[TBL] [Abstract][Full Text] [Related]
13. Combination therapy with indacaterol and glycopyrronium bromide in the management of COPD: an update on the evidence for efficacy and safety.
Ridolo E; Montagni M; Riario-Sforza GG; Baroni M; Incorvaia C
Ther Adv Respir Dis; 2015 Apr; 9(2):49-55. PubMed ID: 25691493
[TBL] [Abstract][Full Text] [Related]
14. [Medication of the month. Indacaterol (Onbrez Breezhaler) and chronic obstructive pulmonary disease].
Corhay JL; Louis R
Rev Med Liege; 2011 Sep; 66(9):498-502. PubMed ID: 21995240
[TBL] [Abstract][Full Text] [Related]
15. LANTERN: a randomized study of QVA149 versus salmeterol/fluticasone combination in patients with COPD.
Zhong N; Wang C; Zhou X; Zhang N; Humphries M; Wang L; Thach C; Patalano F; Banerji D;
Int J Chron Obstruct Pulmon Dis; 2015; 10():1015-26. PubMed ID: 26082625
[TBL] [Abstract][Full Text] [Related]
16. Cost Effectiveness of the Long-Acting β2-Adrenergic Agonist (LABA)/Long-Acting Muscarinic Antagonist Dual Bronchodilator Indacaterol/Glycopyrronium Versus the LABA/Inhaled Corticosteroid Combination Salmeterol/Fluticasone in Patients with Chronic Obstructive Pulmonary Disease: Analyses Conducted for Canada, France, Italy, and Portugal.
Reza Maleki-Yazdi M; Molimard M; Keininger DL; Gruenberger JB; Carrasco J; Pitotti C; Sauvage E; Chehab S; Price D
Appl Health Econ Health Policy; 2016 Oct; 14(5):579-94. PubMed ID: 27516088
[TBL] [Abstract][Full Text] [Related]
17. When Two Drugs Are Better than Three: Re-Modulating the Therapeutic Plan of a Chronic Obstructive Pulmonary Disease Patient.
Ielpo A; Crisafulli E
Respiration; 2018; 95 Suppl 1():6-10. PubMed ID: 29705779
[TBL] [Abstract][Full Text] [Related]
18. The impact of treatment with indacaterol in patients with COPD: A post-hoc analysis according to GOLD 2011 categories A to D.
Kerstjens HA; Deslée G; Dahl R; Donohue JF; Young D; Lawrence D; Kornmann O
Pulm Pharmacol Ther; 2015 Jun; 32():101-8. PubMed ID: 25743376
[TBL] [Abstract][Full Text] [Related]
19. Indacaterol/Glycopyrronium in Clinical Practice: The Italian Experience.
Cazzola M
Respiration; 2018; 95 Suppl 1():1-2. PubMed ID: 29705778
[No Abstract] [Full Text] [Related]
20. Indacaterol add-on therapy improves lung function, exercise capacity and life quality of COPD patients.
Mroz RM; Minarowski L; Chyczewska E
Adv Exp Med Biol; 2013; 756():23-8. PubMed ID: 22836615
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
